Atezolizumab alleviates the immunosuppression induced by PD‑L1‑positive neutrophils and improves the survival of mice during sepsis

Abstract

Atezolizumab can reduce immunosuppression caused by T lymphocyte apoptosis in various cancer types. The current study aimed to investigate whether this drug can also alleviate immunosuppression during sepsis. For that purpose, a C57BL/6 mouse sepsis model was generated. Mice were randomly assigned to three groups: Sham, cecal ligation and puncture (CLP) and atezolizumab groups. Atezolizumab was administered in vivo by intraperitoneal injection. The expression of programmed death ligand-1 (PD-L1) on neutrophils and programmed death-1 (PD-1) on T lymphocytes was evaluated, and endotoxin concentration, intestinal permeability, ileum histopathological score and tight junction protein expression were assessed to determine the extent of disease in each group. The rate of T lymphocyte apoptosis was determined to assess the effects of atezolizumab on T lymphocyte apoptosis in vivo and in vitro . Survival times were also recorded to compare mouse prognosis during sepsis. In the CLP group, the proportion of PD-L1 + neutrophils was significantly higher at 48, 72 and 96 h in blood, and at 24, 48, 72 and 96 h in bone marrow, compared with those of the sham group (P<0.05). The proportion of PD-1 + T lymphocytes was also upregulated at 72 h in blood. In the atezolizumab group, endotoxin concentration, intestinal permeability and ileum histopathological score were lower compared with those in the CLP group (P<0.05), whereas the expression of claudin-1 and occludin proteins on ileum was higher compared with that in the CLP group (P<0.05). Both in vivo and in vitro experiments indicated that the rate of T lymphocyte apoptosis following atezolizumab treatment was lower compared with that in the CLP group (P<0.05). Survival analysis demonstrated that mice in the atezolizumab group survived longer compared with those in the CLP group (P<0.05). The current study demonstrated that treatment with atezolizumab may be an effective method for treating immunosuppression induced by sepsis.

Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases

“…More work is needed to better comprehend the role of sPD-L1 in the etiology of sepsis. This is important because anti-PD-L1 antibodies (as well as nanobodies and peptides) are being evaluated for the treatment of sepsis [ 174 , 175 , 176 ]. On the other side, rare cases of sepsis induced by PD-L1 inhibitors have been recorded [ 177 ].…”

Stigmasterol Exerts an Anti-Melanoma Property through Down-Regulation of Reactive Oxygen Species and Programmed Cell Death Ligand 1 in Melanoma Cells

“…The combination of chemotherapy and immunotherapy targeting PD-L1/PD-1 has shown promise in improving anti-tumor responses by triggering immune-reactivation via CD8(+) T cells [ 76 ]. The co-incubation of PD-1-expressing CTLL-2 cells, which are CD8(+) T cells and melanoma cells, has been used in cancer research [ 78 , 79 ]. Our findings indicate that STIG enhances the killing effect of CTLL-2 cells on melanoma cells, suggesting its potential application in inducing immunogenic cell death in melanoma.…”

JAC4 Protects from X-ray Radiation-Induced Intestinal Injury by JWA-Mediated Anti-Oxidation/Inflammation Signaling

“…The degree of radiation damage in mice was evaluated, as previously described [ 14 , 15 ]. Histological abnormalities were graded as follows: Grade 0: normal; Grade 1: inflammatory cell infiltration or mucosal bleeding; Grade 2: vacuolization of villi, abnormal crypt direction, or mucosal hypertrophy; Grade 3: submucosal cysts or irregular crypt regeneration of atypical epithelial cells; Grade 4: ulcerative mucosal or transmural necrosis.…”